Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma

Cancer

Volumn 113, Issue 9, 2008, Pages 2496-2503

  Derenzini, Enrico ^a,c   Musuraca, Gerardo ^a   Fanti, Stefano ^b   Stefoni, Vittorio ^a   Tani, Monica ^a   Alinari, Lapo ^a   Venturini, Filippo ^a   Gandolfi, Letizia ^a   Baccarani, Michele ^a   Zinzani, Pier Luigi ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c L and A Seràgnoli Hematology and Oncological Sciences Institute   (Italy)

Author keywords

Autologous stem cell transplantation; Diffuse large B cell lymphoma; Follicular lymphoma; Positron emission tomography; Progression free survival; Secondary age adjusted International Prognostic Index

Indexed keywords

ARABINOSIDE; CARMUSTINE; CYTOSINE; EPIRUBICIN; ETOPOSIDE; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE; MELPHALAN;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLICULAR LYMPHOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; SCORING SYSTEM; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FEMALE; FLUORODEOXYGLUCOSE F18; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IFOSFAMIDE; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MELPHALAN; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; VINCRISTINE;

EID: 55549091716     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23861     Document Type: Article

References (21)

1. Armitage JO. Treatment of non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1023-1030.
2. Coiffer B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.
3. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International (Mint) Group. Lancet Oncol. 2006;7:379-391.
4. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive NHL. N Engl J Med. 1995;333:1540-1545.
5. Vose JM, Anderson JR, Kessinger A, et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol. 1993;11:1846-1851.
6. Hamlin PA, Zelenetz AD, Kewalramani T, et al. Ageadjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2003;102:1989-1996.
7. Zinzani PL, Magagnoli M, Chierichetti F, et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol. 1999;10:1141-1143.
8. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood. 1999;94:429-433.
9. Schot BW, Zjilstra JM, Sluiter WJ, et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood. 2007;109:486-491.
10. Filmont JE, Gisselbrecht C, Cuenca X, et al. The impact of pre and post transplantation positron emission tomography using 18-fluorodeoxyglucose on poor prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer. 2007;110:1361-1369.
11. Svoboda J, Andreadis C, Elstrom R, et al. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant. 2006;38:211-216.
12. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood. 2003;102:53-59.
13. Cremerius U, Fabry U, Wildeberger JE, et al. Pretransplantation positron emission tomography (PET) using fluorine-18-fluorodeoxyglucose (FDG) predicts outcome in patients treated with high dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant. 2002;30:103-111.
14. Zinzani PL. Tani M, Molinari AL, et al. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. Haematologica. 2002;87:816-821.
15. Mikhaeel NG, Timothy AR, O'Doherty MJ, et al. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma - comparison with CT. Leuk Lymphoma. 2000;39:543-553.
16. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244-1249.
17. Kaplan EL, Meier P. Nonparametric estimations from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
18. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187-220.
19. Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol. 2002;13:1356-1363.
20. Mikhaeel NG, Hutchings M, Fields PA, et al. FDG-PET after 2 to 3 cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol. 2005;16:1514-1523.
21. Haioun C, Itti E, Rahmouni A, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005;106:1376-1381.